Abstract CT187: A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor (CAR)γδT cell therapy, in patients (pts) with relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC) (trial in progress)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409822075